Journals / Türkiye Aile Hekimliği Dergisi / 2005 / Cilt: 9 - Sayı: 2

Prolactinoma: A case report and current and approach to hyperprolactinemia

Prolaktinoma: Olgu sunumu ve hiperprolaktinemiye güncel yaklaşım

Pages
85–89
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article we review guidelines which can help the diagnosis and treatment of hyperprolactinemia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prolactin is a hormon secreted from anterior hypophysis.
📊
Key Findings & Data:Its main functions are lactation, reproduction, growth and osmoregula- tion.
💡
Conclusion & Impact:In this article we review guidelines which can help the diagnosis and treatment of hyperprolactinemia.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Prolactin is a hormon secreted from anterior hypophysis. Its main functions are lactation, reproduction, growth and osmoregula- tion. Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. Hyperprolactinemia often causes hypogonadism and galactorrhea in both sexes, while men- strual dysfunction and infertility in females and empotance in males are the most common symptoms. In addition, there may be neurological symptoms by mass effect in the sellar area if its caused by a macroprolactinoma. Dopamine agonists (bromocrip- tine, pergolide, cabergoline) are the first step choices in the treat- ment. Main indications of surgery in prolactinomas are intoler- ance of the medication, and tumors not responding to dopamine agonists. Occasionally, these may ultimately require radiation therapy. In this article we review guidelines which can help the diagnosis and treatment of hyperprolactinemia.

Özet

Prolaktin, önhipofizden salınan, esas fonksiyonları laktasyon, üreme, büyüme ve osmoregülasyon olan bir hormondur. Hipotalamus-hipofiz aksının en sık rastlanan endokrin bozukluğu hiperprolaktinemidir. Kadınlarda adet düzensizliği ve infertilite, erkeklerde empotans en sık görülen semptomlar iken, hiperpro-laktinemi her iki cinste çoğu kez hipogonadizm ve galaktoreye neden olur. Etken makroprolaktinoma ise sella bölgesinde basıya bağlı nörolojik belirtiler görülebilir. Tedavide ilk seçenek dopamin agonistleri; bromokriptin, pergolid ve kabergolindir. ilaç tedavi­sine tahammülsüzlük ya da cevapsızlık söz konusu ise cerrahi girişim ve sıklıkla da radyasyon tedavisi gerekir. Bu yazı, hiperpro-laktinemi tanı ve tedavisine yardımcı olabilecek bir kılavuz ver­mektedir.

🔖

Cite This Article

TOPRAK, D. (2022). Prolactinoma: A case report and current and approach to hyperprolactinemia. Türkiye Aile Hekimliği Dergisi, Cilt: 9 - Sayı: 2, 85–89. https://ajindex.com/articles/626893

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H. Guidelines for the diagnosis and treat ment of hyperprolactinemia. J Reprod Med 1999; 44(12 Suppl): 1075-84
  2. Nomikos P, Buchfelder M, Fahlbusch R. Current management of pro lactinomas. J Neurooncol 2001; 54: 139-50
  3. Molvalılar S. Ön ve arka hipofiz hastalıkları. Temel iç Hastalıkları’nda. Ed.İliçin G, Ünal S, Biberoğlu K, Akalın S, Süleymanlar. 2. cilt. Ankara, Güneş Kitabevi, 1996; 1688-98
  4. Sonino N, Navarrini C, Ruini C, Fallo F, Boscaro M, Fava GA. Life events in the pathogenesis of hyperprolactinemia. Eur J Endocrinol 2004; 151: 61-5
  5. Rosato F, Garofalo P. Hyperprolactinemia: from diagnosis to treatment. Minerva Pediatr 2002; 54: 547-52
  6. Biler BM. Hyperprolactinemia. Int J Fertil Womens Med 1999; 44: 74-7
  7. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and manage ment. Semin Reprod Med 2002; 20: 365-74
  8. Hershlag A, Matthew C, Çeviri: Günayd›n G, Taner MZ. Endokrin Hastalıklar. Novak Jinekoloji’de. Ed. Berek JS, çeviri ed. Erk A. 13. baskı. İstanbul, Nobel, 2004; 871-930
  9. Chiodini I, Liuzzi A. PRL-secreting pitiutary adenomas in pregnancy. J Endocrinol Invest 2003;26: 96-9
  10. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999; 44(12 Suppl): 1121-6
  11. Molitch ME. Pituitary diseases in pregnancy. Semin Perinatol 1998; 22: 457- 70
  12. Badawy SZ, Marziale JC, Rosenbaum AE, Chang JK, Joy SE. The long term effects of pregnancy and bromocriptine treatment on prolactinomas-the value of radiologic studies. Early Pregnancy 1997; 3: 306-11
  13. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002; 11: 787-800
  14. Colao A, Di Sarno A, Cappabianca P, Di Soma C, Pivonello R, Lombardini G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003 20; 349: 2023-33
  15. Davis JR. Prolactin and reproductive medicine. Curr Opin Obstet Gynecol 2004;16: 331-7
  16. Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003; 6: 19-27
  17. Webster J. Clinical management of prolactinomas. Baillieres Best Pract Res. Clin Endocrinol Metab 1999; 13: 395-408
  18. Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002; 87: 3578-82
  19. Molitch ME. Disorders of